News
News
On April 10, 2012 a 42 center worldwide trial of PRRT using LU177 was announced with sites in the US and Europe.
Detailed Description:
A multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study. In this study, treatment with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care (30 mg Octreotide LAR) will be compared to treatment with high dose (60 mg) Octreotide LAR in patients with inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours; these patients should be progressive under Octreotide LAR. In case patients in either arm experience clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections are
Dr. Richard P. Baum, was honored by the Society of Nuclear Medicine, India in Chennai on December 8, 2011 and received the AGASTHIAR AWARD for his "Life Time Contribution to The Field of Nuclear Medicine". Prof. Baum was also appointed "Visiting Professor" of the FM Medical University (Tandu Hospital) in Xi'an, Shaanxi, China where he initiated a project on Ga-68 imaging and PRRNT which will be the first place in China where THERANOSTICS will be performed. The initial effort for this endeavor came from a Chinese patient who lives in Singapore and received PRRNT in Bad Berka.
Bad Berka, Germany
With over 350 participants from 30 countries representing the 5 continents, the 1st World Congress on GA68 and PRRNT marks a historical moment in the history of imaging and therapy for individuals with Neuroendocrine tumors as well as other diseases that can be imaged with GA68.
Please enjoy the photo gallery below. Viewing on an iPhone, iPad or other device that does not support flash? click here.
The final program has been announced for the 1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy to be held June 23rd-26th, 2011 in Bad Berka, Germany.
Please click here to download the agenda.
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers.
Published in Journal of Clinical Oncology, 2011 May 9;[Epub Ahead of Print], A Imhof, P Brunner, N Marincek, M Briel, C Schindler, H Rasch, HR Mäcke, C Rochlitz, J Müller-Brand, MA Walter
To read a review of the JCO article please visit OncologyStat (free registration is required to read the summary of findings.)